Slate Medicines raises $130m in funds to progress anti-PACAP treatments

The funding aligns with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio ...
PharmiWeb

Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders

Lead program, SLTE-1009, licensed from DartsBio Pharmaceuticals (Guangdong), Ltd, is a potentially best-in-class anti-PACAP ...